1
|
Wang S, Pang Z, Fan H, Tong Y. Advances in anti-EV-A71 drug development research. J Adv Res 2024; 56:137-156. [PMID: 37001813 PMCID: PMC10834817 DOI: 10.1016/j.jare.2023.03.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2023] [Revised: 03/05/2023] [Accepted: 03/21/2023] [Indexed: 03/31/2023] Open
Abstract
BACKGROUND Enterovirus A71 (EV-A71) is capable of causing hand, foot and mouth disease (HFMD), which may lead to neurological sequelae and even death. As EV-A71 is resistant to environmental changes and mutates easily, there is still a lack of effective treatments or globally available vaccines. AIM OF REVIEW For more than 50 years since the HFMD epidemic, related drug research has been conducted. Progress in this area can promote the further application of existing potential drugs and develop more efficient and safe antiviral drugs, and provide useful reference for protecting the younger generation and maintaining public health security. KEY SCIENTIFIC CONCEPTS OF REVIEW At present, researchers have identified hundreds of EV-A71 inhibitors based on screening repurposed drugs, targeted structural design, and rational modification of previously effective drugs as the main development strategies. This review systematically introduces the current potential drugs to inhibit EV-A71 infection, including viral inhibitors targeting key sites such as the viral capsid, RNA-dependent RNA polymerase (RdRp), 2C protein, internal ribosome entry site (IRES), 3C proteinase (3Cpro), and 2A proteinase (2Apro), starting from each stage of the viral life cycle. Meanwhile, the progress of host-targeting antiviral drugs and their development are summarized in terms of regulating host immunity, inhibiting autophagy or apoptosis, and regulating the cellular redox environment. In addition, the current clinical methods for the prevention and treatment of HFMD are summarized and discussed with the aim of providing support and recommendations for the treatment of enterovirus infections including EV-A71.
Collapse
Affiliation(s)
- Shuqi Wang
- College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China
| | - Zehan Pang
- College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China
| | - Huahao Fan
- College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
| | - Yigang Tong
- College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China; Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing, China.
| |
Collapse
|
2
|
Wei Y, Hu D, Li D, Hu K, Zhang Q, Liu H, He Q, Yao C, Li H, Wang J. Antiviral effects and mechanisms against EV71 of the novel 2-Benzoxyl-Phenylpyridine Derivatives. Eur J Pharm Sci 2023; 186:106445. [PMID: 37044201 DOI: 10.1016/j.ejps.2023.106445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2023] [Revised: 03/31/2023] [Accepted: 04/10/2023] [Indexed: 04/14/2023]
Abstract
A series of 2-Benzoxyl-Phenylpyridine derivatives were evaluated for their potential antiviral activities against EV71. The preliminary assays indicated that some of these compounds exhibited excellent antiviral effects on EV71, they could effectively inhibit virus-induced cytopathic effects (CPEs), reduce progeny viral yields, and present similar or better antiviral activities compared to the positive control drug ribavirin. Among these derivatives, compounds WY7, WY13 and WY14 showed the most potency against EV71. Investigation of the underlying mechanism of action revealed that these compounds target EV71 replication in cells post infection, they could profoundly inhibit viral RNA replication and protein synthesis, and inhibit virus-induced cell apoptosis. Further experiments demonstrated that compound WY7 potently inhibited the activity of the EV71 3C protease (3Cpro), and to some extent, it affected the activity of 3D polymerase (3Dpol), thus blocking viral replication, but not the activity of the 2A proteinase (2Apro). Modeling of the molecular binding of the 3Cpro-WY7 complex revealed that compound WY7 was predicted to insert into the substrate-binding pocket of EV71 3Cpro, blocking substrate recognition and thereby inhibiting EV71 3Cpro activity. These results indicate that these compounds might be feasible therapeutic agents against EV71 infection and that these compounds may provide promising lead scaffolds for the further design and synthesis of potential antiviral agents.
Collapse
Affiliation(s)
- Yanhong Wei
- Sino-German Biomedical Center, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Key Laboratory of Industrial Microbiology, School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China.
| | - Da Hu
- Sino-German Biomedical Center, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Key Laboratory of Industrial Microbiology, School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China.
| | - Dong Li
- Sino-German Biomedical Center, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Key Laboratory of Industrial Microbiology, School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China.
| | - Kanghong Hu
- Sino-German Biomedical Center, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Key Laboratory of Industrial Microbiology, School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China.
| | - Qian Zhang
- Sino-German Biomedical Center, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Key Laboratory of Industrial Microbiology, School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China.
| | - Huihui Liu
- Sino-German Biomedical Center, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Key Laboratory of Industrial Microbiology, School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China.
| | - Qun He
- Sino-German Biomedical Center, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Key Laboratory of Industrial Microbiology, School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China.
| | - Chenguang Yao
- Sino-German Biomedical Center, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Key Laboratory of Industrial Microbiology, School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China.
| | - Hanluo Li
- Sino-German Biomedical Center, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Key Laboratory of Industrial Microbiology, School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China.
| | - Jun Wang
- Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
| |
Collapse
|
3
|
Mao C, Cao Z, Fu B, Wang S, Chen H, Xia C, Hu X, Huang X, Qin C. Synthesis of 5-arylidene-3-(pyridin-4-yl)-2-thio-imidazolidinone derivatives with the end of flexible chain modified with aryl groups under microwave. SYNTHETIC COMMUN 2022. [DOI: 10.1080/00397911.2022.2047727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Chongyang Mao
- Institute of Biomedical Materials Industry Technology, Hubei Co-Innovation Center for Utilization of Biomass Waste, College of Chemistry and Materials Science, Hubei Engineering University, Xiaogan, Hubei, China
| | - Zhen Cao
- Institute of Biomedical Materials Industry Technology, Hubei Co-Innovation Center for Utilization of Biomass Waste, College of Chemistry and Materials Science, Hubei Engineering University, Xiaogan, Hubei, China
| | - Boqiao Fu
- Institute of Biomedical Materials Industry Technology, Hubei Co-Innovation Center for Utilization of Biomass Waste, College of Chemistry and Materials Science, Hubei Engineering University, Xiaogan, Hubei, China
| | - Shengcheng Wang
- Institute of Biomedical Materials Industry Technology, Hubei Co-Innovation Center for Utilization of Biomass Waste, College of Chemistry and Materials Science, Hubei Engineering University, Xiaogan, Hubei, China
| | - Haowei Chen
- Institute of Biomedical Materials Industry Technology, Hubei Co-Innovation Center for Utilization of Biomass Waste, College of Chemistry and Materials Science, Hubei Engineering University, Xiaogan, Hubei, China
| | - Caifen Xia
- Institute of Biomedical Materials Industry Technology, Hubei Co-Innovation Center for Utilization of Biomass Waste, College of Chemistry and Materials Science, Hubei Engineering University, Xiaogan, Hubei, China
| | - Xinliang Hu
- Institute of Biomedical Materials Industry Technology, Hubei Co-Innovation Center for Utilization of Biomass Waste, College of Chemistry and Materials Science, Hubei Engineering University, Xiaogan, Hubei, China
| | - Xinyuan Huang
- College of Life Science and Technology, Hubei Engineering University, Xiaogan, Hubei, China
| | - Caiqin Qin
- Institute of Biomedical Materials Industry Technology, Hubei Co-Innovation Center for Utilization of Biomass Waste, College of Chemistry and Materials Science, Hubei Engineering University, Xiaogan, Hubei, China
| |
Collapse
|
4
|
Kaur N, Singh P, Banerjee P. Vinylogous Aza‐Michael Addition of Urea Derivatives with
p
‐Quinone Methides Followed by Oxidative Dearomative Cyclization: Approach to Spiroimidazolidinone Derivatives. Adv Synth Catal 2021. [DOI: 10.1002/adsc.202100077] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Navpreet Kaur
- Department of Chemistry Indian Institute of Technology Ropar Rupnagar Punjab 140001 India
| | - Priyanka Singh
- Department of Chemistry Indian Institute of Technology Ropar Rupnagar Punjab 140001 India
| | - Prabal Banerjee
- Department of Chemistry Indian Institute of Technology Ropar Rupnagar Punjab 140001 India
| |
Collapse
|
5
|
Hsieh CF, Jheng JR, Lin GH, Chen YL, Ho JY, Liu CJ, Hsu KY, Chen YS, Chan YF, Yu HM, Hsieh PW, Chern JH, Horng JT. Rosmarinic acid exhibits broad anti-enterovirus A71 activity by inhibiting the interaction between the five-fold axis of capsid VP1 and cognate sulfated receptors. Emerg Microbes Infect 2020; 9:1194-1205. [PMID: 32397909 PMCID: PMC7448925 DOI: 10.1080/22221751.2020.1767512] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2020] [Revised: 04/30/2020] [Accepted: 05/02/2020] [Indexed: 01/08/2023]
Abstract
Enterovirus A71 (EV-A71), a positive-stranded RNA virus of the Picornaviridae family, may cause neurological complications or fatality in children. We examined specific factors responsible for this virulence using a chemical genetics approach. Known compounds from an anti-EV-A71 herbal medicine, Salvia miltiorrhiza (Danshen), were screened for anti-EV-A71. We identified a natural product, rosmarinic acid (RA), as a potential inhibitor of EV-A71 by cell-based antiviral assay and in vivo mouse model. Results also show that RA may affect the early stage of viral infection and may target viral particles directly, thereby interfering with virus-P-selectin glycoprotein ligand-1 (PSGL1) and virus-heparan sulfate interactions without abolishing the interaction between the virus and scavenger receptor B2 (SCARB2). Sequencing of the plaque-purified RA-resistant viruses revealed a N104K mutation in the five-fold axis of the structural protein VP1, which contains positively charged amino acids reportedly associated with virus-PSGL1 and virus-heparan sulfate interactions via electrostatic attraction. The plasmid-derived recombinant virus harbouring this mutation was confirmed to be refractory to RA inhibition. Receptor pull-down showed that this non-positively charged VP1-N104 is critical for virus binding to heparan sulfate. As the VP1-N104 residue is conserved among different EV-A71 strains, RA may be useful for inhibiting EV-A71 infection, even for emergent virus variants. Our study provides insight into the molecular mechanism of virus-host interactions and identifies a promising new class of inhibitors based on its antiviral activity and broad spectrum effects against a range of EV-A71.
Collapse
Affiliation(s)
- Chung-Fan Hsieh
- Department of Biochemistry and Molecular Biology, College of Medicine, Chang Gung University, Taoyuan, Taiwan
| | - Jia-Rong Jheng
- Department of Biochemistry and Molecular Biology, College of Medicine, Chang Gung University, Taoyuan, Taiwan
| | - Guan-Hua Lin
- Department of Biochemistry and Molecular Biology, College of Medicine, Chang Gung University, Taoyuan, Taiwan
| | - Yu-Li Chen
- Department of Biochemistry and Molecular Biology, College of Medicine, Chang Gung University, Taoyuan, Taiwan
| | - Jin-Yuan Ho
- Department of Biochemistry and Molecular Biology, College of Medicine, Chang Gung University, Taoyuan, Taiwan
| | - Chien-Jou Liu
- Department of Biochemistry and Molecular Biology, College of Medicine, Chang Gung University, Taoyuan, Taiwan
| | - Kuei-Yang Hsu
- Department of Biochemistry and Molecular Biology, College of Medicine, Chang Gung University, Taoyuan, Taiwan
| | - Yuan-Siao Chen
- Genomics Research Center, Academia Sinica, Taipei, Taiwan
| | - Yoke Fun Chan
- Department of Medical Microbiology, University Malaya, Kuala Lumpur, Malaysia
| | - Hui-Ming Yu
- Genomics Research Center, Academia Sinica, Taipei, Taiwan
| | - Pei-Wen Hsieh
- Graduate Institute of Natural Products, College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Research Center for Industry of Human Ecology and Graduate Institute of Health Industry Technology, Chang Gung University of Science and Technology, Taoyuan, Taiwan
- Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
| | - Jyh-Haur Chern
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan, ROC
| | - Jim-Tong Horng
- Department of Biochemistry and Molecular Biology, College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Graduate Institute of Natural Products, College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Research Center for Emerging Viral Infections and Healthy Aging Research Center, College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Molecular Infectious Disease Research Center, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan
| |
Collapse
|
6
|
Zhang M, Wang Y, He W, Sun Y, Guo Y, Zhong W, Gao Q, Liao M, Wang X, Cai Y, Guo Y, Rao Z. Design, Synthesis, and Evaluation of Novel Enterovirus 71 Inhibitors as Therapeutic Drug Leads for the Treatment of Human Hand, Foot, and Mouth Disease. J Med Chem 2020; 63:1233-1244. [PMID: 31939669 DOI: 10.1021/acs.jmedchem.9b01414] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Human hand, foot, and mouth disease (HFMD) is a serious public health threat with high infection rates in children and infants who reside in Asia and the Pacific regions, and no effective drugs are currently available. Enterovirus 71 (EV71) and coxsackievirus A16 are the major etiological pathogens. Based on an essential hydrophobic pocket on the viral capsid protein VP1, we designed and synthesized a series of small molecular weight compounds as inhibitors of EV71. A potential drug candidate named NLD-22 exhibited excellent antiviral activity (with an EC50 of 5.056 nM and a 100% protection rate for mice at a dose of 20 mg/kg) and low toxicity. NLD-22 had a favorable pharmacokinetic profile. High-resolution cryo-electron microscopy structural analysis confirmed NLD-22 bound to the hydrophobic pocket in VP1 to block viral infection. In general, NLD-22 was indicated to be a promising potential drug candidate for the treatment of HFMD.
Collapse
Affiliation(s)
- Min Zhang
- State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences and College of Pharmacy , Nankai University , Tianjin 300353 , China.,Drug Discovery Center for Infectious Diseases , Nankai University , Tianjin 300350 , People's Republic of China
| | - Ying Wang
- Tianjin International Joint Academy of Biotechnology and Medicine , Tianjin 300457 , China
| | - Wanli He
- State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences and College of Pharmacy , Nankai University , Tianjin 300353 , China
| | - Yao Sun
- National Laboratory of Macromolecules, Institute of Biophysics , Chinese Academy of Science , Beijing 100101 , China
| | - Yan Guo
- State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences and College of Pharmacy , Nankai University , Tianjin 300353 , China
| | - Weilong Zhong
- Department of Gastroenterology and Hepatology, Tianjin Institute of Digestive Disease , Tianjin Medical University General Hospital , Tianjin 300052 , China
| | - Qiang Gao
- Sinovac Biotech Co., Ltd , Beijing 100085 , China
| | - Mingyang Liao
- National Beijing Center for Drug Safety Evaluation and Research , Beijing Institute of Pharmacology and Toxicology , 27 Taiping Road , Beijing 100850 , China
| | - Xiangxi Wang
- National Laboratory of Macromolecules, Institute of Biophysics , Chinese Academy of Science , Beijing 100101 , China
| | - Yan Cai
- Tianjin International Joint Academy of Biotechnology and Medicine , Tianjin 300457 , China
| | - Yu Guo
- State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences and College of Pharmacy , Nankai University , Tianjin 300353 , China.,Tianjin International Joint Academy of Biotechnology and Medicine , Tianjin 300457 , China.,Drug Discovery Center for Infectious Diseases , Nankai University , Tianjin 300350 , People's Republic of China.,Frontiers Science Center for Cell Responses , Nankai University , Tianjin 300350 , People's Republic of China
| | - Zihe Rao
- State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences and College of Pharmacy , Nankai University , Tianjin 300353 , China.,Tianjin International Joint Academy of Biotechnology and Medicine , Tianjin 300457 , China.,National Laboratory of Macromolecules, Institute of Biophysics , Chinese Academy of Science , Beijing 100101 , China.,Drug Discovery Center for Infectious Diseases , Nankai University , Tianjin 300350 , People's Republic of China.,Frontiers Science Center for Cell Responses , Nankai University , Tianjin 300350 , People's Republic of China
| |
Collapse
|
7
|
Egorova A, Ekins S, Schmidtke M, Makarov V. Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses. Eur J Med Chem 2019; 178:606-622. [PMID: 31226653 PMCID: PMC8194503 DOI: 10.1016/j.ejmech.2019.06.008] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2019] [Revised: 06/03/2019] [Accepted: 06/03/2019] [Indexed: 01/16/2023]
Abstract
The hydrophobic pocket within viral capsid protein 1 is a target to combat the rhino- and enteroviruses (RV and EV) using small molecules. The highly conserved amino acids lining this pocket enable the development of antivirals with broad-spectrum of activity against numerous RVs and EVs. Inhibitor binding blocks: the attachment of the virion to the host cell membrane, viral uncoating, and/or production of infectious virus particles. Syntheses and biological studies of the most well-known antipicornaviral capsid binders have been reviewed and we propose next steps in this research.
Collapse
Affiliation(s)
- Anna Egorova
- Bach Institute of Biochemistry, Research Center of Biotechnology of the Russian Academy of Sciences, Leninsky prospekt 33-2, Moscow, 119071, Russia
| | - Sean Ekins
- Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC27606, USA
| | - Michaela Schmidtke
- Jena University Hospital, Department of Medical Microbiology, Section Experimental Virology, Hans-Knöll-Str. 2, 07745, Jena, Germany
| | - Vadim Makarov
- Bach Institute of Biochemistry, Research Center of Biotechnology of the Russian Academy of Sciences, Leninsky prospekt 33-2, Moscow, 119071, Russia.
| |
Collapse
|
8
|
Li D, Ollevier T. Synthesis of Imidazolidinone, Imidazolone, and Benzimidazolone Derivatives through Oxidation Using Copper and Air. Org Lett 2019; 21:3572-3575. [PMID: 31058508 DOI: 10.1021/acs.orglett.9b00973] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
A new synthetic method of urea derivatives using copper and air was developed. These mild conditions provided moderate to very good yields for 15 examples (53-93%), while low yields were obtained with sterically hindered substrates (3 examples). The reaction was found to go through an in situ generated copper- N-heterocyclic carbene, which was then oxidized into cyclic urea derivatives possessing alkyl, benzyl, aryl, hydroxy, Boc-protected, and tertiary amine groups.
Collapse
Affiliation(s)
- Dazhi Li
- Département de chimie , Université Laval , 1045 avenue de la Médecine , Québec , QC , G1V 0A6 , Canada
| | - Thierry Ollevier
- Département de chimie , Université Laval , 1045 avenue de la Médecine , Québec , QC , G1V 0A6 , Canada
| |
Collapse
|
9
|
Swain SP, Mohanty S. Imidazolidinones and Imidazolidine‐2,4‐diones as Antiviral Agents. ChemMedChem 2019; 14:291-302. [DOI: 10.1002/cmdc.201800686] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2018] [Revised: 12/18/2018] [Indexed: 01/12/2023]
Affiliation(s)
- Sharada Prasanna Swain
- Department of Process ChemistryDr. Reddy's Lab Ltd. CTO-III, IDA, Bollaram Hyderabad 502325 India
| | - Sandeep Mohanty
- Department of Process ChemistryDr. Reddy's Lab Ltd. CTO-III, IDA, Bollaram Hyderabad 502325 India
| |
Collapse
|
10
|
Li P, Yu J, Hao F, He H, Shi X, Hu J, Wang L, Du C, Zhang X, Sun Y, Lin F, Gu Z, Xu D, Chen X, Shen L, Hu G, Li J, Chen S, Xiao W, Wang Z, Guo Q, Chang X, Tian X, Lin T. Discovery of Potent EV71 Capsid Inhibitors for Treatment of HFMD. ACS Med Chem Lett 2017; 8:841-846. [PMID: 28835799 DOI: 10.1021/acsmedchemlett.7b00188] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2017] [Accepted: 07/10/2017] [Indexed: 11/28/2022] Open
Abstract
Enterovirus 71 (EV71) is a major causative agent of hand, foot, and mouth disease (HFMD), which can spread its infections to the central nervous and other systems with severe consequences. The viral caspid protein VP1 is a well-known target for antiviral efficacy because its occupancy by suitable compounds could stabilize the virus capsid, thus preventing uncoating of virus for RNA release. In this Letter, design, synthesis, and biological evaluation of novel anti-EV71 agents (aminopyridyl 1,2,5-thiadiazolidine 1,1-dioxides) are described. One of the most promising compounds (14) showed excellent antiviral activity against EV71 (EC50 = 4 nM) and exhibited excellent in vivo efficacy in the EV71 infected mouse model.
Collapse
Affiliation(s)
- Peng Li
- WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe Zhong Road, Shanghai 200131, People’s Republic of China
- State
Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen, Fujian 361102, People’s Republic of China
| | - Jun Yu
- WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe Zhong Road, Shanghai 200131, People’s Republic of China
| | - Fei Hao
- WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe Zhong Road, Shanghai 200131, People’s Republic of China
| | - Haiying He
- WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe Zhong Road, Shanghai 200131, People’s Republic of China
| | - Xuyang Shi
- WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe Zhong Road, Shanghai 200131, People’s Republic of China
| | - Jiao Hu
- WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe Zhong Road, Shanghai 200131, People’s Republic of China
| | - Li Wang
- WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe Zhong Road, Shanghai 200131, People’s Republic of China
| | - Chunyan Du
- WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe Zhong Road, Shanghai 200131, People’s Republic of China
| | - Xiao Zhang
- WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe Zhong Road, Shanghai 200131, People’s Republic of China
| | - Ya Sun
- WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe Zhong Road, Shanghai 200131, People’s Republic of China
| | - Fusen Lin
- WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe Zhong Road, Shanghai 200131, People’s Republic of China
| | - Zhengxian Gu
- WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe Zhong Road, Shanghai 200131, People’s Republic of China
| | - Deming Xu
- WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe Zhong Road, Shanghai 200131, People’s Republic of China
| | - Xinsheng Chen
- WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe Zhong Road, Shanghai 200131, People’s Republic of China
| | - Liang Shen
- WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe Zhong Road, Shanghai 200131, People’s Republic of China
| | - Guoping Hu
- WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe Zhong Road, Shanghai 200131, People’s Republic of China
| | - Jian Li
- WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe Zhong Road, Shanghai 200131, People’s Republic of China
| | - Shuhui Chen
- WuXi AppTec (Shanghai) Co., Ltd., 288 FuTe Zhong Road, Shanghai 200131, People’s Republic of China
| | - Wei Xiao
- Jiangsu Kanion Pharmaceutical Co., Ltd., 58 Haichangnan Road, Lianyungang 222001, People’s Republic of China
| | - Zhenzhong Wang
- Jiangsu Kanion Pharmaceutical Co., Ltd., 58 Haichangnan Road, Lianyungang 222001, People’s Republic of China
| | - Qingming Guo
- Jiangsu Kanion Pharmaceutical Co., Ltd., 58 Haichangnan Road, Lianyungang 222001, People’s Republic of China
| | - Xiujuan Chang
- Jiangsu Kanion Pharmaceutical Co., Ltd., 58 Haichangnan Road, Lianyungang 222001, People’s Republic of China
| | - Xuyang Tian
- State
Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen, Fujian 361102, People’s Republic of China
| | - Tianwei Lin
- State
Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen, Fujian 361102, People’s Republic of China
| |
Collapse
|
11
|
Yang Y, Guan F, Bai L, Zhang L, Liu J, Pan X, Zhang L. Quinolizidine alkaloids reduced mortality in EV71-infected mice by compensating for the levels of T cells. Bioorg Med Chem Lett 2015; 25:3526-8. [DOI: 10.1016/j.bmcl.2015.06.097] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2015] [Accepted: 06/25/2015] [Indexed: 11/28/2022]
|
12
|
Mineeva IV. Cyclopropanol methodology in the synthesis of (4R)- and (4S)-4-methyltetrahydro-2H-pyran-2-ones. Application in the synthesis of insect pheromones with methyl-branched carbon skeleton. RUSSIAN JOURNAL OF ORGANIC CHEMISTRY 2015. [DOI: 10.1134/s1070428015030094] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
13
|
Xiao JA, Wang CM, Wang J, Ou GC, Zhang XY, Yang H. Highly stereoselective synthesis of novel spiroimidazolidinones directed by pyridine prolinamide. Tetrahedron 2015. [DOI: 10.1016/j.tet.2014.12.055] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
14
|
Pan J, Han X, Sun N, Wu H, Lin D, Tien P, Zhou HB, Wu S. Synthesis of N-benzyl-N-phenylthiophene-2-carboxamide analogues as a novel class of enterovirus 71 inhibitors. RSC Adv 2015. [DOI: 10.1039/c5ra07286g] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A series ofN-benzyl-N-phenylthiophene-2-carboxamide analogues were identified as novel human enterovirus 71 inhibitors with EC50values up to 1.42 μM.
Collapse
Affiliation(s)
- Jiawei Pan
- College of Life Sciences
- Wuhan University
- Wuhan 430072
- China
- State Key Laboratory of Virology
| | - Xin Han
- State Key Laboratory of Virology
- Wuhan University School of Pharmaceutical Sciences
- Wuhan 430071
- China
| | - Ningyuan Sun
- College of Life Sciences
- Wuhan University
- Wuhan 430072
- China
| | - Haoming Wu
- College of Life Sciences
- Wuhan University
- Wuhan 430072
- China
| | - Dandan Lin
- Department of Oncology
- Renmin Hospital of Wuhan University
- Wuhan 430060
- China
| | - Po Tien
- College of Life Sciences
- Wuhan University
- Wuhan 430072
- China
| | - Hai-Bing Zhou
- State Key Laboratory of Virology
- Wuhan University School of Pharmaceutical Sciences
- Wuhan 430071
- China
| | - Shuwen Wu
- College of Life Sciences
- Wuhan University
- Wuhan 430072
- China
| |
Collapse
|
15
|
Tang X, Xue F, Ma H, Cao X, Chen C, Li X. Synthesis and antifungal activity of d-glucopyranosyl ureas and d-glucofurano-imidazolidine-2-ones. RESEARCH ON CHEMICAL INTERMEDIATES 2013. [DOI: 10.1007/s11164-012-0596-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Yao S, Chen H, Jiang S, Shao X, Cui S. Density functional theory study on the reaction mechanism of synthesizing 1,3-dimethyl-2-imidazolidinone by urea method. J Mol Model 2012; 19:49-55. [DOI: 10.1007/s00894-012-1499-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2011] [Accepted: 06/07/2012] [Indexed: 11/30/2022]
|
17
|
Yang Y, Zhang L, Fan X, Qin C, Liu J. Antiviral effect of geraniin on human enterovirus 71 in vitro and in vivo. Bioorg Med Chem Lett 2012; 22:2209-11. [PMID: 22342145 DOI: 10.1016/j.bmcl.2012.01.102] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2011] [Revised: 01/24/2012] [Accepted: 01/25/2012] [Indexed: 12/17/2022]
Abstract
Human enterovirus 71 infection causes hand, foot and mouth disease in children under 6 years of age and has caused mortalities in large-scale outbreaks in the Asia-Pacific region. No effective vaccine or antiviral drugs currently exist against enterovirus 71 in the clinic. In this study, we investigated the antiviral effect of geraniin on enterovirus 71 both in vitro and in vivo. The results showed that geraniin effectively inhibited virus replication in rhabdomyosarcoma cells with an IC(50) of 10 μg/ml. Moreover, geraniin treatment of mice that were challenged with a lethal dose of enterovirus 71 resulted in a reduction of mortality, relieved clinical symptoms, and inhibited virus replication in muscle tissues. The results suggest that geraniin may be used as a potential drug for anti-enterovirus 71.
Collapse
Affiliation(s)
- Yajun Yang
- Key Laboratory of Human Diseases Comparative Medicine, Ministry of Health, Institute of Laboratory Animal Science, CAMS & Comparative Medicine Centre, PUMC, Beijing, China
| | | | | | | | | |
Collapse
|
18
|
Li H, Song F, Widenhoefer RA. Gold(I)-Catalyzed Intramolecular Hydroamination of N-Allylic,N'-Aryl Ureas to form Imidazolidin-2-ones. Adv Synth Catal 2011; 353:955-962. [PMID: 21709731 PMCID: PMC3122478 DOI: 10.1002/adsc.201000844] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Treatment of N-allylic,N'-aryl ureas with a catalytic 1:1 mixture of di-tert-butyl-o-biphenylphoshphine gold(I) chloride and silver hexafluorophosphate (1 mol %) in chloroform at room temperature led to 5-exo hydroamination to form the corresponding imidazolidin-2-ones in excellent yield. In the case of N-allylic ureas that possessed an allylic alkyl, benzyloxymethyl, or acetoxymethyl substituent, gold(I)-catalyzed 5-exo hydroamination leads to formation of the corresponding trans-3,4-disubstituted imidazolidin-2-ones in excellent yield with ≥50:1 diastereoselectivity.
Collapse
Affiliation(s)
- Hao Li
- Duke University, French Family Science Center, Durham, North Carolina, USA. Fax: +1-919-660-1605; Tel: +1-919-660-1533
| | - Feijie Song
- Duke University, French Family Science Center, Durham, North Carolina, USA. Fax: +1-919-660-1605; Tel: +1-919-660-1533
| | - Ross A. Widenhoefer
- Duke University, French Family Science Center, Durham, North Carolina, USA. Fax: +1-919-660-1605; Tel: +1-919-660-1533
| |
Collapse
|
19
|
Hung HC, Chen TC, Fang MY, Yen KJ, Shih SR, Hsu JTA, Tseng CP. Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid. J Antimicrob Chemother 2010; 65:676-83. [PMID: 20089540 PMCID: PMC7110181 DOI: 10.1093/jac/dkp502] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Objectives Enterovirus 71 (EV71) causes serious diseases in humans. The aim of this study was to examine the effects of aurintricarboxylic acid (ATA) on EV71 replication and to explore the underlying mechanism. Methods To measure the activity of ATA in inhibiting the cytopathic effect (CPE) of EV71, a cell-based neutralization (inhibition of virus-induced CPE) assay was performed. The effect of ATA was further confirmed using plaque reduction and viral yield reduction assays. A time of addition assay was performed to identify the mechanisms of ATA's anti-EV71 activity. We examined the effects of ATA on the following key steps involved in virus replication: (i) translation of the internal ribosomal entry site (IRES)-mediated viral polyprotein; (ii) the proteolytic activity of viral proteases 2A and/or 3C; and (iii) the viral 3D RNA-dependent RNA polymerase (RdRp) activity. Results In this study, ATA was found to be a potent inhibitor of the replication of EV71. In the antiviral neutralization assay, ATA exhibited inhibitory activity against EV71 (TW/4643/98) and EV71 (TW/2231/98). Plaque assay further demonstrated that ATA inhibited EV71 replication with an EC50 (effective concentration at which 50% of plaques were removed) of 2.9 µM. Studies on the mechanism of action revealed that ATA targets the early stage of the viral life cycle after viral entry. ATA was able to inhibit the RdRp activity of EV71, while neither the IRES-mediated translation of viral polyprotein nor the viral 3C protease activity was affected. Conclusions Overall, the findings in this study suggest that ATA is able to effectively inhibit EV71 replication through interfering with the viral 3D polymerase.
Collapse
Affiliation(s)
- Hui-Chen Hung
- Department of Biological Science and Technology, National Chiao Tung University, Hsin-Chu, Taiwan
| | | | | | | | | | | | | |
Collapse
|
20
|
DasGupta S, Murumkar PR, Giridhar R, Yadav MR. Studies on novel 2-imidazolidinones and tetrahydropyrimidin-2(1H)-ones as potential TACE inhibitors: design, synthesis, molecular modeling, and preliminary biological evaluation. Bioorg Med Chem 2009; 17:3604-17. [PMID: 19394232 DOI: 10.1016/j.bmc.2009.04.003] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2009] [Revised: 03/31/2009] [Accepted: 04/01/2009] [Indexed: 12/18/2022]
Abstract
Compounds belonging to the class of 2-imidazolidinones and tetrahydropyrimidin-2(1H)-ones were synthesized and evaluated for their TACE inhibitory activity. Most of the compounds showed very good TACE inhibitory activity. Docking study clearly indicates importance of the P1' group of the inhibitor for the TACE inhibitory activity. This work proves that these two classes of molecules could be used as potential leads for the development of TACE inhibitors.
Collapse
Affiliation(s)
- Shirshendu DasGupta
- Pharmacy Department, Faculty of Technology and Engineering, Kalabhavan, The M. S. University of Baroda, Vadodara 390 001, Gujarat, India
| | | | | | | |
Collapse
|
21
|
De Palma AM, Vliegen I, De Clercq E, Neyts J. Selective inhibitors of picornavirus replication. Med Res Rev 2008; 28:823-84. [PMID: 18381747 DOI: 10.1002/med.20125] [Citation(s) in RCA: 181] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Picornaviruses cover a large family of pathogens that have a major impact on human but also on veterinary health. Although most infections in man subside mildly or asymptomatically, picornaviruses can also be responsible for severe, potentially life-threatening disease. To date, no therapy has been approved for the treatment of picornavirus infections. However, efforts to develop an antiviral that is effective in treating picornavirus-associated diseases are ongoing. In 2007, Schering-Plough, under license of ViroPharma, completed a phase II clinical trial with Pleconaril, a drug that was originally rejected by the FDA after a New Drug Application in 2001. Rupintrivir, a rhinovirus protease inhibitor developed at Pfizer, reached clinical trials but was recently halted from further development. Finally, Biota's HRV drug BTA-798 is scheduled for phase II trials in 2008. Several key steps in the picornaviral replication cycle, involving structural as well as non-structural proteins, have been identified as valuable targets for inhibition. The current review aims to highlight the most important developments during the past decades in the search for antivirals against picornaviruses.
Collapse
Affiliation(s)
- Armando M De Palma
- Rega Institute, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium
| | | | | | | |
Collapse
|
22
|
Antiviral activity of pyridyl imidazolidinones against enterovirus 71 variants. J Biomed Sci 2008; 15:291-300. [PMID: 18196474 DOI: 10.1007/s11373-007-9228-5] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2007] [Accepted: 12/11/2007] [Indexed: 12/20/2022] Open
Abstract
Pyridyl imidazolidinone is a novel class of capsid binder which can inhibit enterovirus 71 (EV71). In this study, we tested the susceptibility of six recombinant viruses with different single-site mutations in VP1. Eleven modified pyridyl imidazolidinones were synthesized and used to probe the interaction between these compounds and the EV71 VP1 protein. We found that the D31N or E98K mutant viruses were susceptible to bulkier compounds, which suggested that mutations at these two sites in VP1 may widen the hydrophobic pocket of VP1, allowing bulkier compounds to enter and interfere VP1-receptor binding. Additionally, the Y116H mutant was more resistant to pyridyl imidazolidinone compounds containing a methyl group in the central position of the hydrophobic linker. When a trifluoromethyl group was substituted for the methyl group in the middle of the linker chain, the inhibitory effect was totally abolished in the Y116H mutant, suggesting that the interaction between Tyr (Y) 116 of VP1 and the central position of the linker chain of pyridyl imidazolodinone is very important for drug efficacy. A V192M mutant was resistant to most of the derivatives, indicating that residue 192 is a key mutation for resistance to pyridyl imidazolidinone.
Collapse
|